1. Volume 152, Issue 1, Pages 53-60 (January 2019)
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer 
Antonio González Martín, Amit M. Oza, Andrew C. Embleton, Jacobus Pfisterer, Jonathan A. Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Monique A. Bertrand, Philip Beale, Andrés Cervantes, Emma Kent, Richard S. Kaplan, Mahesh K.B. Parmar, Nana Scotto, Timothy J. Perren 
Gynecologic Oncology 
Volume 152, Issue 1, Pages (January 2019)
DOI: /j.ygyno
Copyright © 2018 The Authors Terms and Conditions

2. Fig. 1
Distribution of the study population (treatment arms pooled) according to residual disease and stage.
Subgroups in shaded boxes correspond to the Medical Research Council-defined ‘high-risk’ subgroup. NOS, not otherwise specified.
Gynecologic Oncology  , 53-60DOI: ( /j.ygyno )
Copyright © 2018 The Authors Terms and Conditions

3. Fig. 2
Subgroup analyses of efficacy by stage. (A) progression-free survival; (B) overall survival.
CI, confidence interval; HR, hazard ratio.
Gynecologic Oncology  , 53-60DOI: ( /j.ygyno )
Copyright © 2018 The Authors Terms and Conditions

4. Fig. 3 Summary of PFS and OS in patients with stage IIIB–IV disease.
CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.
Gynecologic Oncology  , 53-60DOI: ( /j.ygyno )
Copyright © 2018 The Authors Terms and Conditions

5. Fig. 4
Subgroup analyses of efficacy: (A) PFS and (B) OS; (i) Stage IIIB–IV (n = 1160);
(ii) Stage IIIB–IV with no visible residual disease (n = 411); (iii) Stage IIIB–IV with visible residual disease (n = 749).
CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.
Gynecologic Oncology  , 53-60DOI: ( /j.ygyno )
Copyright © 2018 The Authors Terms and Conditions

6. Fig. 5
Subgroup analyses by stage and residual disease status in the stage III/IV subgroup.
CI, confidence interval; HR, hazard ratio; NR, not reached; OS, overall survival; PFS, progression-free survival.
Gynecologic Oncology  , 53-60DOI: ( /j.ygyno )
Copyright © 2018 The Authors Terms and Conditions